|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intramuscular Ziprasidone 2 mg versus 10 mg in the short term management of agitaed psychotic patients显示文摘 | Zajecka JM Swift RH | 2001 | J Clin psychiatry2001，62，： | 1 |
| 2 | Intramuscular ziprasi: done, 2rag verrsus10mg, in the short--term management of agitated paschotie patients显示文摘 | Lesem MD Zajecka JM Swift RH | 2001 | J Clin Psychiatry2001，62，： | 1 |
| 3 | Morbidity and mortality in the Wolfram syndrome显示文摘 | Kinsley BT Swift M Dumont RH | 1995 | Diabetes Care1995，18，12： | 1 |
| 4 | Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients显示文摘 | LESEM MD ZAJECKA JM SWIFT RH | 2001 | J Clin Psychiatry2001，62，1： | 1 |
| 5 | Intramuscular ziprasidone 2 mg versus 10 mg in the short - term management of agitated psychotic patients 显示文摘 | Lesem MD Zajecka JM Swift RH | 2001 | J Clin Psychiatry2001，62，1： | 1 |
| 6 | Intramuscular ziprasidone,2mg versus 10mg,in the short-term management of agitated psychotic patients显示文摘 | Lesem DM Zajecka JM Swift RH | 2001 | J Clin Psychiatry2001，62，1： | 1 |
| 7 | Intramuscular ziprasidone , 2mg versus 10mg , in the short-term manage-ent of agitated psychotic patients 显示文摘 | Lesem DM Zajecka JM Swift RH | 2001 | J Clin Psychiatry2001，62，： | 1 |
| 8 | Intramuscular ziprasidone, 2rag versus 10mg, in the short-term managrment of agitated psychotic patients显示文摘 | Lesem MD Zajecka JM Swift RH | 2001 | J Clin psychiatry2001，62，： | 1 |
| 9 | Intramuscular ziprasidone,2 mg versus 10 mg,in the short-term management of agitated psychotic patients显示文摘 | Lesem MD Zajecka JM Swift RH | 2001 | J Clin Psychiarty2001，62，1： | 1 |
| 10 | Intramuscular ziprasidone,2 mg versus 10 mg,in the short-term management of agitated psychotic patients显示文摘 | Lesem MD Zajecka JM Swift RH | | 0，，： | 1 |
| 11 | The tolera- bility of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy 显示文摘 | Daniel DG Zimbroff DL Swift RH | 2004 | Int Clin Psychophar- macol2004，19，1： | 1 |
| 12 | Intramuscular ziprasidone,2 mg versus 10 mg,in the short term management of agitated psychotic patients显示文摘 | Lesem MD Zajecka JM Swift RH | 2001 | J Clin Psychiatry2001，62，1： | 1 |
| 13 | Morbidity and mortality in the Wolfram syndrome显示文摘 | Kinsley BT Swift M Dumont RH | 1995 | Diabetes Care1995，18，： | 1 |
| 14 | Intramuslar ziprasidone,2 mg versus 10 mg, in the short-term manage- ment of agitated psychotic patients显示文摘 | Lesem MD Zaiecka JM Swift RH | 2001 | J Clin Psychiarty2001，62，1： | 1 |
| 15 | Intramuslar ziprasidone ,2 mg versus 10 mg, in the short-term management of agitated psychotic patients 显示文摘 | Lesem MD Zajecka JM Swift RH | 2001 | J Clin Psychiarty2001，62，： | 1 |
| 16 | Intramuscular ziprasidone,2mg versus 10mg,in the short-term management of agitated psychotic patients显示文摘 | Lesem MD Zajecka JM Swift RH | 2001 | J Clin Psychiatry2001，62，： | 1 |
| 17 | Intramuscular ziprasidone, 2 mg versus lomg in the short-term management of agitated psychotic patients显示文摘 | Lesem MD zajecra jM Swift RH | 2001 | J Clin Psychiatry2001，62，1： | 1 |
| 18 | The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy显示文摘 | Daniel DG Zimbroff DL Swift RH | | 0，，： | 1 |
| 19 | Intramuscular ziprasidone, 2 mg versus 10 mg, in the short tern management of agitated psychotic patients显示文摘 | Lesem MD Zajecka JM Swift RH | 2001 | J Clin Psychiatry2001，62，： | 1 |
| 20 | Intramuscular ziprasidone,2mg versus 10mg, in the shortterm management of agitated psychotic patients显示文摘 | Lesem DM Zajecka JM Swift RH | 2001 | J Clin Psychiatry2001，62，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员